Tipranavir: uses, dosing, side effects & brands
Tipranavir is a medicine sold in the U.S. under one brand. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Capsule
- Sold as
- Aptivus
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
Every tipranavir product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Aptivus.
What tipranavir pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| TPV;250 | 250 mg | pink | capsule | — |
Can you crush or split tipranavir?
At least one tipranavirproduct is labelled to be swallowed whole — crushing an extended-release tablet releases the whole day’s dose at once. Which applies depends on the form you were given.
What each tipranavir label says about crushing, splitting and chewingTipranavir and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for tipranavir: levels in milk, effects in breastfed infants, and the drugs it would consider insteadNo published information is available on the use of tipranavir during breastfeeding. Tipranavir is not recommended during breastfeeding. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.
National Institute of Child Health and Human Development, record revised July 15, 2024. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about tipranavir
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,009 reports naming tipranavir, and the FDA flagged 97% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- nausea134 reports
- vomiting128 reports
- pneumonia118 reports
- hepatotoxicity100 reports
- cholelithiasis99 reports
- hepatic enzyme increased96 reports
- oedema peripheral96 reports
- schizophrenia96 reports
Read these as a signal, not a rate. A report does not mean tipranavir caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 26, 2026.
Related calculators
Frequently asked questions
Can you take tipranavir with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run tipranavir against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does tipranavir come in?
Across the brands we track, tipranavir is currently marketed as capsule, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic tipranavir?
We do not currently list a generic-labelled tipranavir product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Tipranavir: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/tipranavir
- MLA
- “Tipranavir: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/tipranavir.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for tipranavir on DailyMed (NIH) ↗.